Transcript presentation.pps

CORPORATE
PRESENTATION
July - 2003
Disclaimer
Except for the historical information
contained herein, statements in this presentation and the subsequent
discussions,which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”,
“expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”,
“goal”, “project”, “should”, “will pursue” and similar expressions or variations of such expressions may
constitute
"forward-looking statements". These
forward-looking statements
involve a number of risks,
uncertainties and other factors that could cause actual results to differ materially from those suggested by the
forward-looking
successfully
statements. These risks and uncertainties include, but are not limited to our ability to
implement our strategy, our
growth and expansion plans,
obtain regulatory approvals, our
provisioning policies, technological changes, investment and business income, cash flow projections, our
exposure to market risks as well as other risks. Ranbaxy does not undertake any obligation to update forwardlooking statements to reflect events or circumstances after the date thereof.
2
Our Mission
“To become a Research based International
Pharmaceutical Company”
3
Our Vision
“To become a Billion Dollar Company
by 2004”
4
Corporate Highlights
•
Amongst the Top 100 Global Pharmaceutical Companies
•
9th Largest Generic Company Worldwide*
•
Manufactures and Markets Generics, Branded Generics and APIs
•
Products available in over 70 countries with Ground presence in
25 countries and Manufacturing operations in 7
•
6 Core Markets - USA, India, UK, Germany, China and Brazil
•
Over 8000 multicultural, workforce
* Amongst Publicly Traded Companies
Source: MedAdNews – Nov’2002
Continued….
5
Corporate Highlights
•
Global Net Sales US $ 764, a growth of 38%
•
72 % Overseas Revenue
•
28 Global Brands
•
NDDS :
*
4 Platform Technologies
*
Cipro OD, once a day ciprofloxacin licensed to Bayer AG. Cipro XR 500mg was
launched in US in Jan 2003 by Bayer AG. Approval from US FDA for 1gm awaited
•
NDDR : RBx 2258, First NCE licensed to Schwarz Pharma AG, undergoing
Phase II Clinical Trials in India
•
2 NDAs filed in 2002 (Metformin syrup, Ofloxacin OD tablets)
NCE = New Chemical Entity , NDDS = Novel Drug Delivery Systems , NDDR = New Drug Discovery Research , NDA = New Drug Application
6
Our International Presence
Core Markets
• USA
• India
• UK
Asia-Pacific &
Latin America
• USA
• India
Middle East
Europe, CIS
& Africa
7
• Germany
• Brazil
• China
• UK
• Ireland
• Poland
• Russia
• Germany
• Ukraine
• South Africa
• Egypt
• Nigeria
• Kenya
• Ivory Coast
• Sri Lanka
• Saudi Arabia
• China
• Vietnam
• Malaysia
• Thailand
• Myanmar
• Singapore
• Brazil
• Mexico
• Peru
• Venezuela
Products Available in over 70 Countries,
Ground Presence in 25 Countries, 6 Core Markets
Ranbaxy’s Strategic Architecture
Horizon 3
Secure future options
Value
Horizon 2
Build momentum of
emerging growth engines
Horizon 1
Drive core growth
Innovative
Research
Specialty
Pharma
International
Generics
•Global Generics Business
•Brand Building in Developed
•Expanding Discovery
•Critical Mass in Focus Markets -
Markets
Research
USA
•Proprietary Technology
•International Clinical
•Leveraging India Advantage
Products
Development
•Networking and Alliances
•Rx Marketing
Time
8
Research & Development : Focus
ANDAs
RANBAXY
NDDR
NDDS
3 Key Areas
NDDS = Novel Drug Delivery Systems , NDDR = New Drug Discovery Research, ANDA = Abbreviated New Drug Application
9
R&D ... Key Priorities
•
•
A New Paradigm for ANDAs
US $Million
Branded products through focussed NDDS
50-60
applications
•
CAGR ~ 50%
Drive Discovery Output and Enhance Early
37
Discovery
•
Exploit Biotech Revolution for Innovative
Pharmaceutical Research
•
•
25
Leverage Alliance Network
Increase Productivity and Shorten
Development Timeline - New Processes,
Automation and Efficient Organisational
Structure
•
10
Develop Leaders at all Levels
2001
2002
R&D Investments
2003
R&D ... Product Strategy
GENERICS
• ANDA filings
SPECIALITY PRODUCTS
• NDDS Products
NCEs
• Long term play
• NDAs , 505 b(2)
• Build expertise in
• Para IVs
• Pseudo Brands
Clinical Development
• Technology and Dosage
• Blockbuster Para IIIs
• Complex Technology and
Niche Products
Forms Innovations
• Research Alliances
• Co-development and
Collaborative Research
• Derma, Paediatric, and
Urology franchise
NCE = New Chemical Entity , NDDS = Novel Drug Delivery Systems , NDA = New Drug Application , ANDA = Abbreviated New Drug Application
11
Drug Discovery Research
NCE Pipeline
Phase 2
RBx 2258
Phase 1
RBx 7796
RBx 7644
Pulmonary Bronchial Asthma
Anti-Bacterial Gram + Infection
IND Filed
Pre-Clinical
Late Discovery
Urology- BPH
RBx 9001
Urology- BPH
RBx 9841
Urology- Overactive Bladder
RBx 6198
RBx 8700
Urology -BPH
Anti-Infective -Tuberculosis
• New Therapeutic Areas
• Metabolic Disorders, Anti-Inflammatory
12
NCE – New Chemical Entity
Novel Drug Delivery Systems
Modified Matrix
8 products launched
Products under development
Gastroretentive
Cipro-OD and Oflox-OD
2 products launched
NDDS
4 Patented Platform Technologies
Multi-particulate
Aerogel
Products under development
Products under development
•
Value Added Drug Delivery Systems for
*
*
*
*
Taste Masking
Effervescent Tablets
Soft Gelatin Capsules
Topical Gels
• Expansion into Transdermal and Inhalers
13
International Regulatory Status
Filings
49
Approvals
Filings
39
Filings
2002
30
2000 and 2001
Approvals
12
Approvals
18
10
7
12
18
32
50
28
25
Filings
Approvals
China
24
11
14
25
64
47
55
41
1999
12
USA
Brazil
Western
Europe
Excludes outsourced ANDAs
14
Research & Development Center
•
Over 800 R&D Personnel
•
Dedicated Facilities for
*
*
•
Drug Discovery Research
*
•
Innovative Research
Generics Research
Therapeutic areas : Urology, Anti-Infectives,
Pulmonary
Novel Drug Delivery Systems
*
*
Focus on Creating Rx products
Expand Technology Platforms
•
Conformance to International Regulatory Framework
•
Multiple Collaborative Research Programs
•
New Technologies / Areas
*
•
R & D– I
Gurgaon, India
Biotechnology , Herbals
Expansion Plan to add 200,000 sq feet area
R & D - II
Gurgaon, India
15
Consolidated Financial Results - 2002
Particulars
Net Sales
EBITDA
% to sales
Operating Earnings before tax
% to sales
Earnings before tax
% to sales
Earnings after tax & minority interests
Dec 2001
(USD Mn)
Dec 2002
(USD Mn)
553
764
77
163
13.8%
21.3%
49
153
8.8%
20.1%
64
172
11.6%
22.4%
56
133
10.1%
17.4%
PBT / Sales
22%
11%
2001
2002
ROCE
38%
% to sales
Return on Capital Employed
16%
2001
EBITDA = Earnings before Interest, Tax, Depreciation & Amortisation
16
2002
Global Sales
US$ Millions
Q2
Particulars
Growth
H1
Growth
2003
2002
(%)
2003
2002
(%)
India and Middle East
54
44
21.5
89
82
8.5
Europe, CIS and Africa
41
23
77.1
73
46
58.7
Asia Pacific and Latin America
16
17
(5.2)
30
28
7.1
USA
101
74
36.6
213
125
70.7
Sub Total
211
158
33.6
405
281
44.2
Active Pharmaceutical Ingredients (API)
24
25
(5.0)
58
50
16.0
6
5
12.0
11
9
22.2
241
189
27.9
474
340
39.5
Dosage Forms
Allied Businesses *
Net Sales
* Animal Healthcare, Diagnostics and Fine Chemicals
17
Business Segment Contribution
2002
Allied
Businesses
3%
API 12%
H1 - 2003
India & Middle
East 23%
Allied
Businesses
2%
API 12%
India & Middle
East 19%
Europe, CIS
Africa 15%
Europe, CIS
Africa 14%
USA 38%
USA 46%
Asia Pacific &
Latin America
10%
18
Asia Pacific &
Latin America
6%
Focus on Pharmaceutical Sales
2002 Dosage Forms contribution at 85%
789**
579
495
358
2000
19
668
Dosage Forms
2002
**Gross Global Sales
444
2001
Manufacturing Strengths
•
Manufacturing Locations in Seven Countries
•
FDA-USA / MCA-UK / MCC-South Africa / TGA-Australia Approved
Facilities
•
Established track record with FDA-USA
•
Successful Partnership with Vendors for Quality Compliance
•
High degree of Backward Integration
•
Cost Leadership
•
Producer of world class Generics, Branded Generics,
Active Pharmaceutical Ingredients and Complex Molecules
•
20
Over 50 in-house APIs developed
Manufacturing Presence
USA
China
Ireland
Malaysia
Active Pharmaceuticals Ingredients (APIs)Facility, Mohali
Nigeria
Dosage Forms Facility, Paonta Sahib]
Active Pharmaceuticals Ingredients (APIs) Facility, Toansa
Dosage Forms Facility, Dewas
India
21
Vietnam
India .. Strengths
•
•
Ranked 3 in Indian Retail Market with Domestic Market Share of 4.63%
Strong Brand Marketing Team with an extensive Distribution Network
*
•
3 brands in top 25
Strong Presence in Anti-Infectives, Cardiovascular, Anti-inflammatory &
Dermatology segments
•
Growing Presence in Central Nervous System and Gastro Intestinal
Tract, areas
•
20 New Products Launched in the H1-2003 period
(Chronic Therapy share 33.3% and Non Anti-infective 59.5%)
•
Largest Field Force comprising 1770 personnel
Source: ORG MAT May 2003
22
USA .. Leading International Expansion
•
•
•
•
•
•
•
•
•
Ranked No. 28 by prescription share
US sales for the H1-2003 were at US $213 Mn.
USA contributes 45% of the global sales (H1-2003)
It is the largest market for the Company
Strong ANDA pipeline
Para IVs ANDAs filed till date ~ 24
Potential first to file for 8-9 out of 24
Brand Market Initiative taken off with over 200 sales representatives.
Increasing Sales & Distribution reach
Sales in US $ Mn
350
296
300
250
200
150
113
100
50
65
42
0
1999
23
2000
2001
2002
Other Core Markets
•
GERMANY
*
*
*
•
UNITED KINGDOM
*
*
*
*
•
Sales US $32 Mn. , growth ~100%(2002)
Largest international player in generics
Ranked 5th in generic segment and 53rd in overall
19 new product launched in 2002 (17 generic, 2 branded)
~ 100 products Approved / Under Received by ANVISA
CHINA
*
*
24
Sales of US $31 Mn. (2002)
Ranked 6th amongst Generics market share of 3.6%
80 product lines
Brand Basket of 6-7 products
BRAZIL
*
*
*
*
*
•
Sales of US $9 Mn.(2002)
Field Force of 43 for promotion to doctors
Focus on Inorganic acquisitions
Secondary sales of ~ US $11.5 Mn. (2002)
Robust Pipeline for year 2003, including Cifran OD & Zanocin OD
Way Forward
•
•
•
•
•
•
•
Building ‘Innovation’ Engine at R&D
Sustain growth momentum in USA
Attain critical mass in Europe and Latin America
Specialty products focus for “Brand” marketing
Fortifying home business – leverage India base
Seeding the Japanese market
Networking, licensing and acquisitions
*
•
25
Technology, new market entry vehicles, brands / proprietary
products
Global talent pool to fuel growth
Our Mission
“To become a Research based International
Pharmaceutical Company”
26
Thank You
27